Association of Kidney Function With Development of Alzheimer Disease and Other Dementias and Dementia-Related Blood Biomarkers

Importance Previous research has suggested an association of kidney function with risk of Alzheimer disease (AD) or other dementias and dementia-related blood biomarkers, but a distinct association remains unclear. Objective To evaluate the association of kidney function with risk of diagnosis of incident AD or dementia within 17 years and with the blood biomarkers neurofilament light (NfL), phosphorylated tau181 (p-tau181), and glial fibrillary acidic protein (GFAP). Design, Setting, and Participants In this prospective, population-based cohort study and nested case-control study, 9940 participants in Germany were enrolled between 2000 and 2002 by their general practitioners and followed up for up to 17 years. Participants were included if information on dementia status and creatinine/cystatin C measurements were available. A subsample of participants additionally had measurements of NfL, p-tau181, and GFAP obtained from blood samples. Statistical analysis was performed from January 3 to November 25, 2022. Exposures Impaired kidney function, based on estimated glomerular filtration rate less than 60 mL/min/1.73 m2 according to the 2021 Chronic Kidney Disease Epidemiology Collaboration creatinine-cystatin C equation. Main Outcomes and Measures All-cause dementia, AD, and vascular dementia diagnosis, as well as log-transformed levels of NfL, p-tau181, and GFAP in blood. Results Of 6256 participants (3402 women [54.4%]; mean [SD] age at baseline, 61.7 [6.6] years), 510 received an all-cause dementia diagnosis within 17 years of baseline. The dementia-related blood biomarker nested case-control sample included 766 participants. After adjusting for age and sex, impaired kidney function at baseline was not associated with a higher risk of all-cause dementia (hazard ratio [HR], 0.95; 95% CI, 0.69-1.29), AD (HR, 0.94; 95% CI, 0.55-1.63), or vascular dementia diagnosis (HR, 1.06; 95% CI, 0.65-1.70) within 17 years. In the cross-sectional analysis, after adjusting for age and sex, impaired kidney function was significantly associated with NfL and p-tau181 levels in blood (NfL: β = 0.47 and P < .001; p-tau181: β = 0.21 and P = .003). After adjusting for age and sex, significant associations with GFAP levels were evident only among men (men: β = 0.31 and P = .006; women: β = -0.12 and P = .11). Conclusions and Relevance In this population-based study of community-dwelling adults, reduced kidney function was associated with increased levels of dementia-related blood biomarkers but not increased dementia risk. Kidney function might influence the accuracy of dementia-related blood biomarkers and should be considered in clinical translation.

[1]  M. Carrillo,et al.  The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[2]  C. Jack,et al.  Performance of plasma phosphorylated tau 181 and 217 in the community , 2022, Nature Medicine.

[3]  D. Rujescu,et al.  Association of plasma biomarkers, p‐tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long‐term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years , 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  P. Rothwell,et al.  Disentangling the Relationship Between Chronic Kidney Disease and Cognitive Disorders , 2022, Frontiers in Neurology.

[5]  Alexa Pichet Binette,et al.  Creatinine and body mass index influence on plasma amyloid ratio, p‐tau217 and neurofilament light , 2021, Alzheimer's & Dementia.

[6]  D. Hyde,et al.  Sex Differences in Behavioral Symptoms and the Levels of Circulating GFAP, Tau, and NfL in Patients With Traumatic Brain Injury , 2021, Frontiers in Pharmacology.

[7]  K. Blennow,et al.  Differences Between Plasma and Cerebrospinal Fluid Glial Fibrillary Acidic Protein Levels Across the Alzheimer Disease Continuum , 2021, JAMA neurology.

[8]  H. Sørensen,et al.  Kidney disease and risk of dementia: a Danish nationwide cohort study , 2021, BMJ Open.

[9]  C. Jack,et al.  Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[10]  N. Powe,et al.  New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. , 2021, The New England journal of medicine.

[11]  O. Hansson.  Biomarkers for neurodegenerative diseases , 2021, Nature Medicine.

[12]  J. Carrero,et al.  Kidney Function, Kidney Function Decline, and the Risk of Dementia in Older Adults , 2021, Neurology.

[13]  Hao-Yang Ma,et al.  Estrogen and estrogen receptors in kidney diseases , 2021, Renal failure.

[14]  K. Blennow,et al.  Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease , 2020, Translational Psychiatry.

[15]  OUP accepted manuscript , 2021, Age And Ageing.

[16]  I. Shimomura,et al.  Renal function is associated with blood neurofilament light chain level in older adults , 2020, Scientific Reports.

[17]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[18]  D. Rujescu,et al.  Prediction of clinical diagnosis of Alzheimer’s disease, vascular, mixed, and all-cause dementia by a polygenic risk score and APOE status in a community-based cohort prospectively followed over 17 years , 2020, Molecular Psychiatry.

[19]  P. Cockwell,et al.  The global burden of chronic kidney disease , 2020, The Lancet.

[20]  I. Saltvedt,et al.  Moderately increased albuminuria, chronic kidney disease and incident dementia: the HUNT study , 2019, BMC Nephrology.

[21]  H. Brenner,et al.  Incident depression and mortality among people with different types of dementia: results from a longitudinal cohort study , 2019, Social Psychiatry and Psychiatric Epidemiology.

[22]  J. Carrero,et al.  Sex and gender disparities in the epidemiology and outcomes of chronic kidney disease , 2018, Nature Reviews Nephrology.

[23]  T. Ninomiya,et al.  Albuminuria Increases the Risks for Both Alzheimer Disease and Vascular Dementia in Community‐Dwelling Japanese Elderly: The Hisayama Study , 2018, Journal of the American Heart Association.

[24]  F. Sohrabji,et al.  Astrocytic response to cerebral ischemia is influenced by sex differences and impaired by aging , 2016, Neurobiology of Disease.

[25]  P. Sachdev,et al.  Risk Factors for Late-Life Cognitive Decline and Variation with Age and Sex in the Sydney Memory and Ageing Study , 2013, PloS one.

[26]  P. Crane,et al.  Relationship Between Longitudinal Measures of Renal Function and Onset of Dementia in a Community Cohort of Older Adults , 2012, Journal of the American Geriatrics Society.

[27]  C. Tzourio,et al.  Chronic kidney disease, cognitive decline, and incident dementia , 2011, Neurology.

[28]  K. Meguro,et al.  Chronic Kidney Disease: A Risk Factor for Dementia Onset: A Population‐Based Study. The Osaki‐Tajiri Project , 2011, Journal of the American Geriatrics Society.

[29]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[30]  H. Brenner,et al.  Epidemiologische Studie zu Chancen der Verhütung, Früherkennung und optimierten Therapie chronischer Erkrankungen in der älteren Bevölkerung (ESTHER-Studie) , 2004 .

[31]  L. Kuller,et al.  Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study. , 2004, Journal of the American Society of Nephrology : JASN.

[32]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .